Clinical significance of cyclin-dependent kinase inhibitor 2C expression in cancers: from small cell lung carcinoma to pan-cancers

Abstract

Background Cyclin-dependent kinase inhibitor 2C (CDKN2C) was identified to participate in the occurrence and development of multiple cancers; however, its roles in small cell lung carcinoma (SCLC) remain unclear. Methods Differential expression analysis of CDKN2C between SCLC and non-SCLC were performed based on 937 samples from multiple centers. The prognosis effects of CDKN2C in patients with SCLC were detected using both Kaplan–Meier curves and log-rank tests. Using receiver-operating characteristic curves, whether CDKN2C expression made it feasible to distinguish SCLC was determined. The potential mechanisms of CDKN2C in SCLC were investigated by gene ontology terms and signaling pathways (Kyoto Encyclopedia of Genes and Genomes). Based on 10,080 samples, a pan-cancer analysis was also performed to determine the roles of CDKN2C in multiple cancers. Results For the first time, upregulated CDKN2C expression was detected in SCLC samples at both the mRNA and protein levels (p of Wilcoxon rank-sum test < 0.05; standardized mean difference = 2.86 [95% CI 2.20–3.52]). Transcription factor FOXA1 expression may positively regulate CDKN2C expression levels in SCLC. High CDKN2C expression levels were related to the poor prognosis of patients with SCLC (hazard ratio > 1, p < 0.05) and showed pronounced effects for distinguishing SCLC from non-SCLC (sensitivity, specificity, and area under the curve ≥ 0.95). CDKN2C expression may play a role in the development of SCLC by affecting the cell cycle. Furthermore, the first pan-cancer analysis revealed the differential expression of CDKN2C in 16 cancers (breast invasive carcinoma, etc.) and its independent prognostic significance in nine cancers (e.g., adrenocortical carcinoma). CDKN2C expression was related to the immune microenvironment, suggesting its potential usefulness as a prognostic marker in immunotherapy. Conclusions This study identified upregulated CDKN2C expression and its clinical significance in SCLC and other multiple cancers, suggesting its potential usefulness as a biomarker in treating and differentiating cancers.

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription

“…5B ). Interestingly, both CDKN1B and CDKN2C are known to mediate cell cycle arrest 46, 47 . As PAXIP1 depletion resulted in slight increased GR chromatin binding around the CDKN1B locus, in contrast to CDKN2C ( Fig.…”

CDCA3 is a potential biomarker for glioma malignancy and targeted therapy

“…Cyclin-dependent kinase CDK2 is a serine/threonine protein kinase that inhibits CDK2 activity by inducing P21 after DNA damage and plays a key role in the G1/S transition. [ 30 , 31 ] Cyclin-dependent kinase inhibitor 2C (CDKN2C) protein encoded by its eponymous gene (CDKN2C), it is a member of the INK4 family. The CDKN2C protein can bind to CDK4 or CDK6 and reduce CDK kinase activation, contributing to cell cycle arrest in the G phase.…”

Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma

“…The increased level of OXTR mRNA may indicate a poor prognosis for patients with colon adenocarcinoma [ 76 ]. CDKN2C expression is linked to TMB and TME, suggesting its potential use as a prognostic marker for immunotherapy [ 77 ]. Finally, H19 is upregulated in multiple types of cancer, including gastric cancer, colorectal cancer, breast cancer, ovarian cancer, and glioma, and also correlates with poor prognosis in these cancers [ 78 – 82 ].…”